Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $140.9 million.

  • United Therapeutics' Cash from Investing Activities rose 22262.84% to $140.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$446.9 million, marking a year-over-year decrease of 17672.1%. This contributed to the annual value of $417.2 million for FY2024, which is 15797.67% up from last year.
  • According to the latest figures from Q3 2025, United Therapeutics' Cash from Investing Activities is $140.9 million, which was up 22262.84% from -$299.9 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Cash from Investing Activities ranged from a high of $735.3 million in Q1 2024 and a low of -$359.2 million during Q1 2022
  • In the last 5 years, United Therapeutics' Cash from Investing Activities had a median value of -$164.7 million in 2025 and averaged -$101.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 560158.73% in 2022, then surged by 43256.45% in 2024.
  • Over the past 5 years, United Therapeutics' Cash from Investing Activities (Quarter) stood at -$195.8 million in 2021, then rose by 3.32% to -$189.3 million in 2022, then surged by 122.24% to $42.1 million in 2023, then tumbled by 392.64% to -$123.2 million in 2024, then surged by 214.37% to $140.9 million in 2025.
  • Its Cash from Investing Activities stands at $140.9 million for Q3 2025, versus -$299.9 million for Q2 2025 and -$164.7 million for Q1 2025.